Patent ID: 8716486

Claim:
A method of treating or suppressing an oxidative stress disorder, comprising administering to a subject in need thereof a therapeutically effective amount of one or more compounds of Formula I: where R is selected from the group consisting of: where the * indicates the point of attachment of R to the remainder of the molecule; n is 0 or 1; R 1 and R 2 are independently selected from the group consisting of hydrogen, (C 1 -C 6 )alkyl, and (C 1 -C 6 )alkoxy; R 3 is (C 1 -C 6 )alkyl or (C 1 -C 6 )alkoxy; R 4 is hydrogen, (C 1 -C 6 )alkyl, hydroxy, or (C 1 -C 6 )alkoxy; Het is optionally substituted pyridine; M and M′ are independently selected from the group consisting of hydrogen, —C(O)—R 10 , —C(O)(C 2 -C 6 )-alkenyl, —C(O)(C 2 -C 6 )-alkynyl, —C(O)-aryl, —C(O)-heterocyclyl, —C(O)O—R 10 , —C(O)NR 10a R 10b , —SO 2 OR 10 , —SO 2 —C 1 -C 6 -alkyl, —SO 2 —(C 1 -C 6 )-haloalkyl, —SO 2 -aryl, —SO 2 —NR 10a R 10b , —P(O)(OR 10a )(OR 10b ), and C-linked amino acid or di-peptide, and R 10 , R 10a , and R 10b are independently hydrogen or (C 1 -C 6 )-alkyl optionally substituted with —OH, —NH 2 , —NH(C 1 -C 4 alkyl), —N(C 1 -C 4 alkyl) 2 , —C(O)OH, —C(O)O—(C 1 -C 4 )-alkyl or halogen; or a pharmaceutically acceptable salt, a solvate, or a hydrate thereof; wherein the oxidative stress disorder is selected from the group consisting of Leber's Hereditary Optic Neuropathy (LHON); Friedreich's Ataxia (FA); CoQ10 deficiency; Parkinson's disease; Huntington's Disease; and diabetes.